Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy of EVT 302, a potent and selective inhibitor of
Monoamine Oxidase - B, in improving quit rates in chronic cigarette smokers who are motivated
to quit smoking. EVT 302 will be compared to placebo both with and without open label
nicotine replacement therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Evotec Neurosciences GmbH
Collaborators:
Clinpharm International Management Holding GmbH PRA Health Sciences